Search - tctmd.com

Displaying 121 - 140 of 254

Sort: Relevancy | Date

News Daily News

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

Shelley Wood

September 30, 2020

News Conference News ESC 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

Caitlin E. Cox

August 31, 2020

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

Todd Neale

August 30, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Daily News

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

L.A. McKeown

June 08, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Daily News ACC 2020

Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT

Shelley Wood

March 17, 2020

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Caitlin E. Cox

February 07, 2020

News Daily News

Most Clinical Trial Sponsors Fail to Report Data as Mandated by FDA

Michael O'Riordan

January 21, 2020

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Shelley Wood

December 23, 2019

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Shelley Wood

November 22, 2019

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Todd Neale

November 17, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Conference News TCT 2019

MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

Shelley Wood

September 29, 2019

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

L.A. McKeown

September 18, 2019

News Daily News

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

L.A. McKeown

September 13, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Daily News

RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators

L.A. McKeown

August 21, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

Advertisement

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Most Clinical Trial Sponsors Fail to Report Data as Mandated by FDA

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Dapagliflozin Has Benefits Across Heart Failure Subgroups

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content